The foundation donated over $1 million to these programs.
The Parkinson’s Foundation announced the recipients of community grants for research on the disease.1 Programs across 40 states received a total of more than $1 million from the foundation, who chose the programs based on their ability to impact local communities and provide support and educational needs for people living with Parkinson’s.
The grants range from $10,000 to $25,000 per program.
In a press release, the foundation’s president and CEO John L. Lehr said, “Community grants help people with PD live better lives, today. These investments reflect the Foundation's continued commitment to meeting unmet needs in the Parkinson's community."
Esther Labib-Kiyarash is a member of the 2024 Community Grant Review Community, along with being a person living with Parkinson’s. In the same press release, she said, “Being a grant reviewer was a reminder of how many people in cities and towns all over the country are working hard to improve the lives of those of us with Parkinson's disease and our care partners. Sometimes it's easy to lose hope, but the really creative and impactful programs that the Parkinson's Foundation is funding gives me so much hope for the future. These programs truly make it possible for people to live better lives with this disease."
In the same press release, Dr. Erika Jackson, PT, DPT, added, “The Community Grant we received from the Parkinson's Foundation will enable us to significantly enhance our rehab programming, providing much-needed support and resources to individuals living with Parkinson's disease. This funding will help us improve the quality of life for our participants, offering them specialized care and rehabilitation services tailored to their unique needs."
Johnson is the co-founder and CEO of Supreme Physical Therapy and Wellness Rehabilitation Center LLC in Houston.
The Parkinson’s Foundation regularly invests in research and testing, along with providing support to local programs. In February of this year, the foundation announced that it had received a grant from the Aligning Science Across Parkinson’s (ASAP) to be used to expand a landmark genetics study.2
In a press release issued at the time, ASAP managing director Ekemini Rily, PhD, said, “ASAP is excited to provide funding to the Parkinson's Foundation to help expand their landmark genetic study PD GENEration, which is, in turn, creating a return of results pathway to those participating in GP2 affiliated studies. We are excited to learn from this pilot in the US and South America and examine ways to expand it globally. As ASAP works to foster collaboration and resource development to accelerate the pace of discovery in Parkinson's disease, we must prioritize diversity and ensure all populations are included in research and clinical trials.”
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.